Momentum behind Sanofi’s novel hemophilia A drug efanesoctocog alfa is building, following the granting of a priority review of the blockbuster-in-waiting by the US regulator.
The Paris-headquartered major is calling its candidate’s efficacy “best in disease” and expects that, once approved, efanesoctocog will rival





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
